Showing results (661-670 of 708) with videos related to

Sort By:
Pageof 71
Archives of Pathology & Laboratory Medicine|March 9, 2025
Standardization of Bone Marrow Reporting for Myelodysplastic Syndromes/Neoplasms on Behalf of the International Consortium for Myelodysplastic Syndromes/NeoplasmsSavanah D Gisriel, Fnu Aakash, John M Bennett, et al.
Cancer|November 14, 2018
Isocitrate dehydrogenase 1 and 2 mutations, 2-hydroxyglutarate levels, and response to standard chemotherapy for patients with newly diagnosed acute myeloid leukemiaAndrew M Brunner, Donna S Neuberg, Seth A Wander, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 4, 2023
Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid LeukemiaAmir T Fathi, Haesook T Kim, Robert J Soiffer, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 10, 2023
NOS inhibition reverses TLR2-induced chondrocyte dysfunction and attenuates age-related osteoarthritisPing Shen, Sebastian Serve, Peihua Wu, et al.
The Journal of Allergy and Clinical Immunology|August 20, 2018
Baseline IL-22 expression in patients with atopic dermatitis stratifies tissue responses to fezakinumabPatrick M Brunner, Ana B Pavel, Saakshi Khattri, et al.
Immunity|February 22, 2023
The alarmin interleukin-33 promotes the expansion and preserves the stemness of Tcf-1+ CD8+ T cells in chronic viral infectionAnna-Friederike Marx, Sandra M Kallert, Tobias M Brunner, et al.
Leukemia & Lymphoma|March 12, 2025
Ixazomib in addition to chemotherapy for the treatment of acute myeloid leukemia in older adultsPhilip C Amrein, Frederic I Preffer, Geoffrey Fell, et al.
American Journal of Hematology|November 23, 2023
Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromesAndrew M Brunner, Jordi Esteve, Kimmo Porkka, et al.
Allergo Journal International|June 28, 2021
Immunologically relevant aspects of the new COVID-19 vaccines-an ÖGAI (Austrian Society for Allergology and Immunology) and AeDA (German Society for Applied Allergology) position paperEva Untersmayr, Elisabeth Förster-Waldl, Michael Bonelli, et al.
Haematologica|December 31, 2016
Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemiaAmir T Fathi, Seth A Wander, Traci M Blonquist, et al.
Pageof 71